The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | QUINTESSENTIAL: a Phase II trial of arlo-cel, a GPRC5D-directed CAR T-cell therapy, in R/R myeloma
Ciara Freeman, MD, PhD, Moffitt Cancer Center, Tampa, FL, discusses the QUINTESSENTIAL trial (NCT06297226), a Phase II study evaluating arlocabtagene autoleucel (arlo-cel), a CAR T-cell therapy targeting GPRC5D, in patients with relapsed/refractory (R/R) multiple myeloma (MM) who have been exposed to all major classes of drugs and are considered quad-exposed. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, on behalf of all of my co-investigators, I’m presenting at this annual meeting a Trials in Progress abstract on the QUINTESSENTIAL study, which is essentially a phase two trial evaluating arlocabtagene autoleucel, or arlo-cel as it’s now called, which is a CAR T-cell therapy that is directed against the GPRC5D target, so a different target to all the BCMA-directed therapies that are already FDA-approved...
So, on behalf of all of my co-investigators, I’m presenting at this annual meeting a Trials in Progress abstract on the QUINTESSENTIAL study, which is essentially a phase two trial evaluating arlocabtagene autoleucel, or arlo-cel as it’s now called, which is a CAR T-cell therapy that is directed against the GPRC5D target, so a different target to all the BCMA-directed therapies that are already FDA-approved. And this trial is evaluating this construct in patients who are quad exposed. So that means they’ve experienced a relapse or been exposed to all the major classes of drugs that we have in our toolbox. So that includes immunomodulators like lenalidomide and pomalidomide, otherwise known as Revlimid and Pomalyst. Similarly, the proteasome inhibitors like Bortezomib and Carfilzomib, or Velcade and Kyprolis, as they’re otherwise known, and the monoclonal antibodies CD38-directed, so daratumumab and isatuximab. And now there’s an additional drug class, so BCMA-directed therapies, that makes them quad-exposed. So they have to have seen in their treatment history all of those agents and progressed and have relapsed and refractory disease in order to be eligible for this study.
So this is a really difficult disease to treat having seen all of our best tools in the toolbox and we’re seeing very encouraging data. So the phase one trial has already been reported out and that data is available with very good high overall response rates and CR rates and we’re waiting to see what the durability of those responses look like and so very exciting to be treating patients with this novel CAR, exciting new option for patients that you know previously they would not have had access to in this late stage of relapsed disease so very exciting to see how this trial goes on and it’s open at over 47 centres in the US and Canada and Japan.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
